DSSG Group: Genitourinary

Advanced Clear Cell Renal Cell Carcinoma (ccRCC)

The goal of this study is to Evaluate Efficacy and Safety of
Pembrolizumab (MK-3475) in Combination with MK-6482 and Lenvatinib (MK-7902), or MK-1308A in Combination with Lenvatinib, versus Pembrolizumab and Lenvatinib, as First line Treatment in Participants with Advanced Clear Cell Renal Cell Carcinoma (ccRCC)

Prostate Cancer being Treated with Stereotactic Body Radiotherapy

To demonstrate the effectiveness of the SpaceOAR Vue System in reducing late gastrointestinal (GI) toxicity in subjects undergoing Stereotactic Body Radiotherapy (SBRT) to treat prostate cancer.

For Patients who previously participated in the BP-007 clinical study

The main purpose of this post marketing clinical follow up is to assess late toxicity and quality of life in subjects who participated in BP-007 clinical study.

Metastatic Castrate Resistant Prostate Cancer (mCRPC).

The purpose of this study is to assess the safety and efficacy of pembrolizumab (MK-3475) combination therapy in patients with metastatic castrate resistant prostate cancer (mCRPC).

Advanced Renal Cell Carcinoma (RCC) with clear cell component after prior therapy

This study will compare the efficacy and safety of belzutifan + lenvatinib versus cabozantinib in participants with advanced renal cell carcinoma (RCC) with clear cell component after prior therapy.

High-Risk Muscle-Invasive Bladder Cancer Who are ctDNA Positive Following Cystectomy (IMvigor011)

The purpose of this trial is to evaluate the efficacy and safety of adjuvant treatment with Atezolizumab compared with placebo in participants with MIBC who are ctDNA positive and are at high risk for recurrence following cystectomy.

Clear Cell Renal Cell Carcinoma (ccRCC) Post Nephrectomy

The purpose of this study is to assess the efficacy and safety of oral Belzutifan (MK-6482) plus intravenous (IV) Pembrolizumab (MK-3475) compared to placebo plus Pembrolizumab, in the adjuvant treatment of Clear Cell Renal Cell Carcinoma (ccRCC) post nephrectomy.

Either very high-risk localised prostate cancer, or very high risk features with PSA persistence or rise within one year following radical prostatectomy, suitable for Radiotherapy.

Determine the effectiveness of adding Darolutamide to androgen deprivation therapy (ADT) and radiation therapy in either the primary definitive setting or very high risk postoperative setting.

Metastatic hormone-sensitive prostate cancer (mHSPC) or castration-resistant prostate cancer (CRPC)

The purpose of this study is to create an international, population-based,
prospective registry of minimum 5,000 men with advanced prostate cancer.

asymptomatic or mildly symptomatic castration resistant prostate cancer patients metastatic to bone

The purpose of this study is to find out whether the combination of Xofigo® (radium-223) and Xtandi® (enzalutamide) shows better activity against Xtandi® alone (enzalutamide) in metastatic prostate cancer and if the combination of Xofigo® (radium-223) and Xtandi® (enzalutamide) is safe.